The rise of Sildenafil initially drove a boom for pharma, however recent changes present a complicated outlook for shareholders. Generic competitors are reducing profits, and continued litigation add additional risk to https://poppypmoy978442.bloginder.com/41805703/viagra-and-big-pharma-a-risky-play